We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Share Name | Share Symbol | Market | Type | Share ISIN | Share Description |
---|---|---|---|---|---|
Oxford Biomedica | AQSE:OXB.GB | Aquis Stock Exchange | Ordinary Share | GB00BDFBVT43 |
Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
---|---|---|---|---|---|---|---|---|---|---|
10.00 | 5.19% | 202.50 | 195.00 | 210.00 | 202.50 | 192.50 | 192.50 | 0.00 | 16:12:47 |
Industry Sector | Turnover | Profit | EPS - Basic | PE Ratio | Market Cap |
---|---|---|---|---|---|
0 | 0 | N/A | 0 |
TIDMOXB
RNS Number : 7574L
Oxford Biomedica PLC
05 October 2016
TR-1: NOTIFICATION OF MAJOR INTEREST IN SHARES(i) ---------------------------------------------------------------------------------------------- 1. Identity of the issuer or OXFORD BIOMEDICA PLC the underlying issuer of existing shares to which voting rights are attached: (ii) --------------------------------------------------------------- ----------------------------- 2 Reason for the notification (please tick the appropriate box or boxes): ---------------------------------------------------------------------------------------------- An acquisition or disposal of voting rights X ------------------------------------------------------------------ -------------------------- An acquisition or disposal of qualifying financial instruments which may result in the acquisition of shares already issued to which voting rights are attached ------------------------------------------------------------------ -------------------------- An acquisition or disposal of instruments with similar economic effect to qualifying financial instruments ------------------------------------------------------------------ -------------------------- An event changing the breakdown of voting rights ------------------------------------------------------------------ -------------------------- Other (please specify): --------------------------------------------------------- ------- -------------------------- 3. Full name of person(s) VULPES LIFE SCIENCES FUND subject to the VULPES TESTUDO FUND notification obligation: (iii) ----------------------------------------------------------- --------------------------------- 4. Full name of shareholder(s) (if different from 3.):(iv) ----------------------------------------------------------- --------------------------------- 5. Date of the transaction 04 OCT 2016 and date on which the threshold is crossed or reached: (v) ----------------------------------------------------------- --------------------------------- 6. Date on which issuer 05 OCT 2016 notified: ----------------------------------------------------------- --------------------------------- 7. Threshold(s) that is/are >18% crossed or reached: (vi, vii) ----------------------------------------------------------- --------------------------------- 8. Notified details: -------------------------------------------------------------------------------------------------------------------------- A: Voting rights attached to shares (viii, ix) -------------------------------------------------------------------------------------------------------------------------- Class/type Situation previous Resulting situation after the of to the triggering triggering transaction shares transaction if possible using the ISIN CODE ------------- ---------------------------------- ----------------------------------------------------------------------- Number Number Number Number of voting % of voting of of of shares rights rights (x) Shares Voting Rights ------------- ---------------- ---------------- -------------- ---------------------------- ------------------------- Direct Direct Indirect Direct Indirect (xi) (xii) ------------- ------------ ------------ -------------- -------------- ------------ ------------ ----------- GB0006648157 475,807,928 475,807,928 575,850,000 575,850,000 18.65% ---------------- ---------------- -------------- -------------- ------------ ------------ ----------- B: Qualifying Financial Instruments -------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------- Type of Expiration Exercise/ Number of voting % of voting financial date Conversion rights that rights instrument (xiii) Period (xiv) may be acquired if the instrument is exercised/ converted. ----------------- -------------- -------------------------------- ------------------------------ --------------------- C: Financial Instruments with similar economic effect to Qualifying Financial Instruments (xv, xvi) -------------------------------------------------------------------------------------------------------------------------- Resulting situation after the triggering transaction -------------------------------------------------------------------------------------------------------------------------- Type of Exercise Expiration Exercise/ Number of voting % of voting financial price date Conversion rights instrument rights instrument (xvii) period refers to (xix, xx) (xviii) --------------- -------------- -------------- ---------------- ------------------------------ ----------------------- Nominal Delta --------------- -------------- -------------- ---------------- ------------------------------ ------------ --------- Total (A+B+C) -------------------------------------------------------------------------------------------------------------------------- Number of voting rights Percentage of voting rights --------------------------------------------------- --------------------------------------------------------------------- 575,850,000 18.65% --------------------------------------------------- --------------------------------------------------------------------- 9. Chain of controlled undertakings through which the voting rights and/or the financial instruments are effectively held, if applicable: (xxi) ------------------------------------------------------------------------------------------ Proxy Voting: ------------------------------------------------------------------------------------------ 10. Name of the proxy holder: ------------------------------------------------------------- --------------------------- 11. Number of voting rights proxy holder will cease to hold: ------------------------------------------------------------- --------------------------- 12. Date on which proxy holder will cease to hold voting rights: ------------------------------------------------------------- --------------------------- 13. Additional information: ------------------------------------------------------------- --------------------------- 14. Contact name: Tim Watts, Chief Financial Officer Oxford BioMedica ------------------------------------------------------------- --------------------------- 15. Contact telephone number: +44 (0) 1865 783 000 ------------------------------------------------------------- ---------------------------
This information is provided by RNS
The company news service from the London Stock Exchange
END
HOLUVAKRNNARRRA
(END) Dow Jones Newswires
October 05, 2016 05:17 ET (09:17 GMT)
1 Year Oxford Biomedica Chart |
1 Month Oxford Biomedica Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions